Core-binding factor (CBF) leukemias, characterized by translocations t(8;21) or inv(16)/t(16;16) targeting the CBF, constitute acute myeloid leukemia (AML) subgroups with favorable prognosis. However, about 40% of patients relapse and the current classification system does not fully reflect this clinical heterogeneity. Previously, gene expression profiling (GEP) revealed two distinct CBF leukemia subgroups displaying significant outcome differences and identified apoptotic signaling, MAPKinase signaling and chemotherapy-resistance mechanisms among the most significant differentially regulated pathways. We now tested different inhibitors of the respective pathways in a cell line model (six cell lines reflecting the CBF subgroup-specific gene expression alterations), and found apoptotic signaling to be differentiating between the CBF subgroup models. In accordance, primary samples from newly diagnosed CBF AML patients (n ¼ 23) also showed differential sensitivity to in vitro treatment with a Smac mimetic such as BV6, an antagonist of inhibitor of apoptosis (IAP) proteins, and ABT-737, a BCL2 inhibitor. Furthermore, GEP revealed the BV6-resistant cases to resemble the previously identified unfavorable CBF subgroup. Thus, our current findings show deregulated IAP expression and apoptotic signaling to differentiate clinically relevant CBF subgroups, which were independent of known molecular markers, thereby providing a starting point for novel therapeutic approaches.
Introduction
Acute myeloid leukemia (AML) is a genetically heterogeneous disease with a proposed multistep pathogenesis. 1 Core-binding factor (CBF) leukemias represent a subgroup of AML characterized by chromosomal aberrations involving the heterodimeric transcription factor CBF, which are likely to be the primary hits. These are t(8;21)(q22;q22), producing the fusion gene RUNX1/ RUNX1T1, and inv(16)(p13.1q22) or t(16;16)(p13.1;q22), resulting in CBFB/MYH11.
2 Both rearrangements result in fusion proteins, which act as dominant negative forms of the transcription factor complex CBF. As the CBF is essential in normal hematopoiesis, 3, 4 its disruption in murine models predisposes to leukemia, but does not lead to leukemia by itself. 5 Like AML, in general, CBF leukemias exhibit also some heterogeneity, which is reflected in their clinical behavior, 6 as well as in their gene expression profiles. 7 As 40-50% of the patients relapse, putting the 'favorable risk' into perspective, 8, 9 it is of great interest to study potential cooperating events in CBF leukemias in order to improve and individualize targeted therapies. 10, 11 In recent years, the more detailed molecular characterization of the disease has provided novel insights with respect to the impact of additional cytogenetic aberrations, 9 molecular aberrations such as mutations of KIT, 11 and recently also aberrant gene expression patterns. 7 Apoptosis, occurring either following triggering of the cell surface death receptors (extrinsic pathway) or involving the mitochondria (intrinsic pathway), is deregulated in most, if not all, cancers. 12, 13 Here, inhibitors of apoptosis (IAP) proteins are known to have an important role in many types of human cancer, including leukemia, and are associated with chemoresistance, disease progression and poor prognosis. 14, 15 Therefore, IAPs are interesting targets for cancer treatment, and currently several small molecule inhibitors of IAPs, for example the dimeric Smac mimetic BV6, 16 are tested in clinical trials. 14 Similarly, BCL2 family members have a crucial role in the intrinsic apoptotic pathway, as the balance of their anti-and pro-apoptotic members regulates the loss of mitochondrial membrane potential and release of cytochrome c, and thus the activation of downstream effectors. 17 As most chemotherapeutic drugs converge on the intrinsic pathway, this balance of BCL2 family members is critical in determining the sensitivity of cells to apoptosis induction by drug treatment. ABT-737, a BH-3 (BCL2 homology domain) mimetic, is to date the most potent described small molecule inhibitor of antiapoptotic BCL2 family members (along with its orally active analog, ABT-263), showing promising in vitro results in combination with established chemotherapeutic drugs. 17, 18 Besides deregulated apoptosis, other pathways frequently activated in different tumors include the classical (RAF/MEK/ERK) MAPKinase pathway, which leads to cell cycle progression and tumor survival. Pathway activation results often from activating mutations in a receptor tyrosine kinase, RAS, BRAF or MEK1, which can be targeted by different small molecule inhibitors currently tested in clinical trials. 19 Another possibility of activating MAPKinase signaling is by PAK1, which promotes cell survival through phosphorylation of BAD and regulates microtubule dynamics by phosphorylation of Stathmin, among others. 20 Alterations in cyclin-dependent kinases (CDKs) often mediate cell cycle defects in cancer, and are also implicated in genomic and chromosomal instability. 21 Our previous gene expression profiling (GEP) study in CBF AML pointed towards the deregulation of apoptotic signaling, MAPKinase signaling, as well as chemotherapy-resistance mechanism pathways as potentially relevant biological basis for the clinical heterogeneity observed in CBF leukemia. 7 As our results were, however, based on mRNA expression differences, the importance of the different pathways on a functional, cellular level remained still suppositional. Therefore, in the current study we investigated the role of the respective pathways by selective inhibition in a cell line model (comprising six cell lines that reflect the previously identified expression patterns), as well as by targeting them in primary CBF AML samples. These analyses demonstrated that deregulated apoptosis seems to indeed underlie the separation into distinct outcome-related CBF subgroups and might therefore constitute an attractive new treatment target in the respective AML cohorts.
Patients and methods

Patient samples and cell lines
Samples (n ¼ 28, of n ¼ 23 distinct cases; n ¼ 10 peripheral blood and n ¼ 18 bone marrow specimens) from adult CBF AML patients at diagnosis were provided by the German-Austrian AML Study Group (AMLSG) with patient informed consent obtained in accordance with the Declaration of Helsinki and institutional review board approval from all participating centers. Patient age at the time of diagnosis ranged from 19.5 to 59.9 years (median 36.9 years). Clinical characteristics at the time of diagnosis were available for almost all cases as detailed in Supplementary Table S1 . All cell lines (HEL, Kasumi-1, ME-1, MONO-MAC-1, MV4-11 and OCI-AML2) were obtained from the DSMZ (German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany).
Cell culture and in vitro treatment
Cell lines were cultivated according to the guidelines of the DSMZ and were always kept within their optimal range of density using RPMI 1640 (Biochrom AG, Berlin, Germany) or a-MEM (GIBCO, Invitrogen Corporation, Grand Island, NY, USA) media, supplemented with 20% fetal calf serum (SigmaAldrich, St Louis, MO, USA), L-glutamin (Biochrom AG), penicillin/streptomycin (GIBCO), sodium pyruvate (GIBCO) and NEAA (non-essential amino acids, GIBCO) as necessary. For in vitro treatment experiments, cell line aliquots were stained with trypan blue (Sigma-Aldrich) and counted to obtain a measure of both cell viability (exclusion criterion at o95% viability) and density. Cell lines were again split to the lower end of their optimal density range to ensure optimal growth conditions and treated with the different agents and controls, according to the respective protocol. The procedure for primary CBF AML samples was the same; before treatment cells were stained with trypan blue, counted, and diluted to a density of 1.0 Â 10 6 cells/ml. Thawing of viably frozen samples followed the DSMZ guideline. Agents used to treat cell lines and primary CBF AML sample were dimethyl sulfoxide (Sigma-Aldrich), ara-C (cytarabine; cell pharm, Bad Vilbel, Germany), BV6 (kindly supplied by Genentech, South San Francisco, CA, USA), ABT-737 (Selleck, Houston, TX, USA), IPA-3 (1,1-disulfanediyldinaphthalen-2-ol; Sigma-Aldrich), PD98059 (2 0 -amino-3 0 -methoxyflavone; GIBCO), olomoucine (2-(hydroxyethylamino)-6-benzylamino-9-methylpurine; Promega, Madison, WI, USA) and colchicine (Sigma-Aldrich) at indicated concentrations.
Viability assays
We performed an ATP-content measurement using the CellTiter-Glo Luminescent Cell Viability Assay (Promega), which reflects the amount of viable cells per sample. For readout, we used the GloMax 96 luminometer (Promega GmbH, Mannheim, Germany). Furthermore, we performed flow cytometry in selected samples, which were double stained using Annexin V-PE (BD Pharmingen, Franklin Lakes, NJ, USA) and 7-AAD (7-amino-actinomycin D; BD Pharmingen) according to the manufacturer's protocol, and measured using a FACSCalibur (BD Pharmingen). FACS and CellTiter-Glo measurements correlated very well (r40.95, Supplementary Figure  S1 ). All treated samples were normalized to appropriate control treated samples. Cell lines were harvested after 48 h of treatment. Primary CBF leukemia samples were measured after 24 h, as after 48 h the viable cell fraction was generally too small to allow a detection of small differences in treatment sensitivity. 
Quantitative reverse transcriptase PCRs
Western blot analysis
Total cell extracts were fractionated on 12% or 4-12% sodium dodecyl sulfate polyacrylamide gels (NuPAGE Bis-Tris Gels; Invitrogen) and electroblotted to polyvinylidene difluoride membranes (Immobilon-P; Millipore, Billerica, MA, USA). Membranes were reacted with anti-Caspase-3 (#9662; Cell Signaling Technology, Danvers, MA, USA), anti-BCL2 (ab37899; Abcam, Cambridge, UK), anti-cIAP2 (#1040-1; Epitomics, Burlingame, CA, USA), anti-b-actin (ab8227; Abcam) or anti-a-tubulin (ab7291; Abcam), followed by incubation with secondary horseradish peroxidase-linked antibodies (GE Healthcare, Fairfield, CT, USA). Immunoreactivity was determined using ECL Western Blotting detection reagents (GE Healthcare).
GEP
Previously published cDNA microarrays data of 93 CBF AML cases available through Gene Expression Omnibus (accession number GSE8653) were included in the study and data were filtered and normalized as reported. 7 Furthermore, we profiled gene expression in 12 additional CBF AML samples using GeneChip Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA, USA; GEO accession GSE29883). Cel files were normalized and filtered using BRB Array Tools (Biometric Research Branch (BRB) ArrayTools software; BRB, National Cancer Institute, Bethesda, MD, USA) by applying the JustRMA algorithm and previously reported filtering criteria (13355 genes passed filtering). 7 Exemplary technical validation of microarraybased gene expression findings was performed with qRT-PCR using SYBR Green I in previous work. 10 
Data analysis
Microarray data were analyzed using BRB Array Tools Version 3.7.2, developed by Dr Richard Simon and Amy Peng Lam, as previously described. 10 For hierarchical clustering average-linkage hierarchical clustering was applied in Cluster and results visualized using TreeView (http://rana.lbl. gov/EisenSoftware.htm). 22 Groupwise comparisons of the distributions of clinical and laboratory variables were performed using Mann-Whitney U-test, unpaired t-test with Welch correction, Fisher's exact test, Kolmogorov-Smirnov test, Wilcoxon test and Pearson's w 2 -test, as appropriate. All tests were two-sided. An effect was considered significant if the P-value was 0.05 or less. Data was visualized using either SigmaPlot (Systat Software, San Jose, CA, USA) or GraphPad Prism 4 (GraphPad Software, La Jolla, CA, USA).
Results
Cell line model for CBF leukemia subgroups
Previously, GEP revealed two distinct CBF leukemia subgroups displaying significant outcome differences, which might in part be attributed to a deregulation of different essential pathways. 7 In order to further characterize these GEP-defined CBF subgroups, we were looking for cell line models reflecting the expression differences between the two subgroups and therefore compared 18 leukemia cell line expression profiles with those of the respective CBF cohorts. Hierarchical clustering analysis, based on 8556 differentially expressed genes, suggested several leukemia cell lines as potential models for the respective groups. Figures S2 and S3 ), three cell lines were identified to be representative for each CBF subgroup, with both subgroup models including a CBF leukemia-derived cell line. The CBF subgroup with inferior outcome was represented by ME-1, MONO-MAC-1, and OCI-AML2 (group 1 cell lines), whereas Kasumi-1, HEL, and MV4-11 (group 2 cell lines) were representative for the superior outcome CBF subgroup.
Based on qRT-PCR and western blot validation (Supplementary
There exist only three CBF leukemia-derived cell lines worldwide, Kasumi-1 (t(8;21)), SKNO-1 (t(8;21) which is growth factor (GM-CSF) dependent and not available via the DSMZ (German Collection of Microorganisms and Cell Cultures)) and ME-1 (inv (16)). This was, together with our hypothesis that a secondary, cooperative class I change in CBF leukemias might also be found in other AML subgroups, the reason why we included non-CBF cell lines into our model. Treatment of the model cell lines with cytarabine (ara-C), a standard chemotherapy treatment in AML, revealed a differential response to the drug ( Figure 1 ): as anticipated, the cell lines resembling the inferior outcome CBF cohort (group 1) were less sensitive to ara-C than those modeling the good prognostic subgroup (group 2). Interestingly, both CBF leukemia cell lines (Kasumi-1 with a t(8;21) and ME-1 with an inv(16)) did not show a complete loss of viability even at higher doses of ara-C, unlike the other cell lines. EC 50 (half maximal effective concentration) values were between 2.3 and 5.5 mM ara-C for the inferior outcome group, and between 0.1 and 1.4 mM ara-C for the superior outcome group. Thus, our model cell lines reflect the distinct GEP-defined CBF leukemia subgroups not only in their expression profiles, but also in their response to ara-C. Therefore, we considered them a suitable model for further characterization of the functional differences underlying the respective CBF subgroups.
Pathway analysis and choice of agents for specific intervention
First, we reassessed our previous pathway comparison analysis, 7 using the most recent BioCarta pathway annotations. In general, results were confirmed and included the top pathways, which were already previously determined as significantly differentially regulated between the two groups. We decided to focus on apoptosis-related pathways and MAPKinase-related signaling, as there were several connected pathways differentially regulated between the two groups. Furthermore, we included the pathway 'Stathmin and breast cancer resistance to antimicrotubule agents' (abbreviated Stathmin pathway) in our screen, as it has been connected to MAPKinase signaling and to treatment resistance in breast cancer. 23 For each of these three pathway groups, we picked two different agents for specific intervention in the respective signaling pathways ( 24 (allosteric PAK1 inhibitor) and PD98059 (selective inhibitor of MEK1), which was shown to inhibit cell growth and survival of AML cell lines while sensitizing them to drug-induced apoptosis. 25 Intervention agents for the Stathmin pathway were olomoucine, a purine derivative inhibiting CDK1 and other cell cycle regulating CDKs, and colchicine, a microtubule depolymerizing agent isolated from nature, which also interacts with Stathmin family proteins. 26, 27 Inhibitor screen (single treatment) in cell line models
The six model cell lines ME-1, MONO-MAC-1, OCI-AML2, HEL, Kasumi-1 and MV4-11 were treated with the different agents using a range of different concentrations, and viability was measured after 48 h (Figure 2a) . Specific intervention in the apoptotic signaling revealed a differential response of the two CBF subgroup model cell lines. For the Smac mimetic BV6, sensitivity to treatment was in general higher in the group 2 cell lines corresponding to the favorable outcome CBF subgroup (Figure 2a ). However, in both subgroup models one cell line was non-responsive to BV6 treatment, even at higher dosage (HEL and OCI-AML2). Excluding these, EC 50 values were at 0.48 and 3.25 mM for the group 2 cell lines and 8 and 410 mM for the group 1 cell lines (modeling the inferior outcome CBF subgroup). Treatment with the BCL2 inhibitor ABT-737 resulted in an inverse response, with the group 1 cell lines exhibiting greater sensitivity to treatment (EC 50 0.12-0.17 mM) than the group 2 cell lines (EC 50 1.56-2.69 mM). Notably, one cell line of each cluster behaved divergently (Figure 2b ): MONO-MAC-1, the only group 1 cell line with low BCL2 expression and an EC 50 of 410 mM ABT-737, was in the range of the other group 2 cell lines, and MV4-11, the group 2 cell line with high BCL2 expression, had an EC 50 of 0.23 mM in range with the sensitive group 1 cell lines.
For the MAPKinase signaling, neither of the two inhibitors revealed a differential response of the two cell line groups. For PD98059, a MEK1 inhibitor, EC 50 values of 84-116 mM and of 87-148 mM were observed for group 1 and group 2, respectively. Treatment with the PAK1 inhibitor IPA-3 also resulted in similar sensitivity of both groups, with EC 50 values of 8.3-11 mM for the group 1 cell lines and of 6.1-8.5 mM for the group 2 cell lines (for an overview of all EC 50 values, see Figure 2c ).
Specific intervention in the Stathmin pathway resulted in a differential response of the cell lines, but again did not reveal a differential response according to the two cell line groups. Inhibiting tubulin polymerization with colchicine revealed EC 50 values of around 0.01-0.1 mM for both groups, with one exception (ME-1 of group 1, 0.22 mM). Treatment with the CDK1 inhibitor olomoucine required EC 50 doses around 53.6-132.1 mM for group 1 cell lines and around 44.2-115.8 mM for group 2 cell lines.
Thus, intervention in apoptosis signaling revealed differential sensitivity of the two cell line groups, both for BV6 and ABT-737 treatment, whereas we did not observe a differential response for any of the other interventions. These findings suggested that not all gene expression differences between the two CBF subgroups result in functional differences on a cellular level, which might be targeted by an inhibitor. As we observed a distinct sensitivity to inhibitor treatment only for BV6 and ABT-737, we focused our further efforts on deregulated apoptosis signaling.
Combination treatment with ara-C As novel therapies usually have to be used as combination therapies with standard chemotherapy, we wanted to assess the potential of BV6 to sensitize for ara-C induced apoptosis, and thus the model cell lines were simultaneously treated with a subtoxic concentration of BV6 (as determined by our screening) and increasing concentrations of ara-C for 48 h. All cell lines showed at least a positive additive effect of the two drugs, as the measured viability after combination treatment was at or below the viability predicted for an additive effect according to Bliss' independence rule 28, 29 ( Figure 3 ).
Treatment of primary CBF AML samples
Based on the differential response to BV6 and ABT-737 treatment, we next treated mononuclear cells (mostly leukemic blasts) derived from newly diagnosed CBF AML patients with either ara-C, ABT-737 or BV6 in vitro for 24 h (Figure 4 ). FACS measurements confirmed this loss of viable cells as apoptosis in a dose-dependent manner (Supplementary Figure S4) . Treatment with ara-C served as a standard chemotherapy control and treatment response ranged from EC 50 values of 3-25 mM, with some samples not even responding at the highest dosage (100 mM ara-C).
In vitro treatment of primary samples with the IAP inhibitor BV6 revealed two distinct groups, with Bone third of the cases (9/23; 39%) not responding well to treatment. The majority of cases (14/23; 61%) exhibited a fair (25-50% viability at 10 mM BV6) to strong (o25% viability at 10 mM BV6) response to BV6 treatment. Both response groups comprised t(8;21) and inv (16) cases, with 63% (5/8) of the t(8;21) and 27% (4/15) of the inv (16) samples in the non-responsive group.
Following BCL2 inhibitor ABT-737 treatment, there was also a differential response observed. Here, 11 of 19 cases (58%) showed a fair to strong response (less than 50% viability at 1 mM ABT-737), and eight cases (42%) were categorized as weakly responsive (more than 50% viability at 1 mM ABT-737). Again, both response groups comprised t(8;21) and inv(16) cases, with 25% (2/8) of the t(8;21) and 55% (6/11) of the inv(16) samples in the non-responsive group. In contrast to the cell line model results, treatment response of primary samples to BV6 or ABT-737 was not generally reversed, as 11 samples showed a 'same direction' response (sensitive or resistant to both agents) and eight samples were characterized by an 'opposite direction' response (sensitive to one, resistant to the other agent) ( Table 2) . As far as molecular aberrations (mutations of KIT, NRAS, FLT3) were concerned, neither BV6 nor ABT-737 response was associated with any of the measured mutations ( Table 2) .
Correlation of gene expression levels with treatment response to BV6 and ABT-737
To investigate whether the BV6 response is correlated with expression levels of genes, which might have a role in the sensitivity of a sample to BV6, we measured BCL2, BIRC2, BIRC3, NFKB1, TNF and XIAP levels in untreated diagnostic samples by qRT-PCR, and used ACTB expression levels for normalization ( Figure 5 ). We observed highly significant differences (Po0.001) in the expression levels of BIRC3 and NFKB1 between BV6 sensitive and resistant cases, as well as significant differences (Po0.005) in the levels of BIRC2 and XIAP. For all these genes, mean expression levels were lower in the BV6-resistant cases. Regarding the ABT-737 response groups, we did not observe statistically significant differences in the expression levels of the measured genes in qRT-PCR (Supplementary Figure S5) . Expression levels of additional genes implicated in response to treatment were compared based on the corresponding microarray data. Here, we observed significantly lower levels of MCL1 in ABT-737 sensitive samples (Supplementary Figure S6) . Furthermore, RIPK1 expression was significantly higher in BV6-sensitive samples (Supplementary Figure S7) .
BV6 treatment response correlates with prognostic CBF leukemia subgroups
In order to see whether the gene expression profiles underlying either BV6 or ABT-737 response were similar to our initial observation, we profiled gene expression in 12 diagnostic, untreated primary CBF AML cases (n ¼ 3 t(8;21) and n ¼ 9 inv (16)), for which BV6 treatment response data had been collected and which represented the overall distribution of BV6 responsiveness (5/12 cases were resistant to BV6, as defined above, and 7/12 were sensitive to BV6 treatment). Regarding the ABT-737 treatment response, seven samples were sensitive (64%, see definition above) and four samples were resistant (36%), again resembling the overall ABT-737 responsiveness as measured in our CBF cohort (for one sample, ABT-737 treatment was not possible due to limited material).
Comparison of BV6 sensitive versus resistant cases resulted in a distinct gene expression signature. Using the SAM (Significance Analysis of Microarrays) algorithm, which accounts for multiple testing, 855 genes were found to be significantly differentially regulated between the different BV6 response groups. Here, we observed some overlap with our previous, outcome-related CBF subgroup signature including differential expression of FOXO1, AKAP13, PICALM and MAP4K4, among others (Supplementary Table S2) . A pathway comparison analysis of the two BV6 response groups (sensitive vs resistant) found 43 of 267 investigated BioCarta pathways to be differentially regulated, with more genes differentially expressed among the two groups than expected by chance (Supplementary  Table S3 ). These included those pathways on which we had initially focused our analysis, the 'MAPKinase signaling pathway', 'p38 MAPK signaling pathway' (significant in Goeman's global test), 'Role of mitochondria in apoptotic signaling' and 'Caspase cascade in apoptosis'. The main component deregulated in the originally listed 'Stathmin and breast cancer resistance to antimicrotubule agents', CDK1, was again found to be differentially expressed between the BV6 response groups, as found in two cell cycle pathways ('Cyclins and cell cycle regulation', 'Cell cycle:G1/S check point').
To assess whether the BV6 treatment sensitivity in vitro did indeed separate the CBF cases into groups corresponding to the CBF subgroups as described previously, we clustered the newly profiled CBF GEPs with our previous AML cohort consisting of 93 cDNA microarrays ( Figure 6 ). 7 Unsupervised average linkage clustering based on the CBF subgroup defining signature revealed that all BV6-resistant cases, together with one sensitive case, clustered with the inferior outcome CBF cases of subgroup 1. The remaining six BV6 sensitive cases clustered with the superior outcome subgroup 2 CBF AML samples. Regarding the ABT-737 sensitivity of the clustered cases, no differences were observed: two of four ABT-737-resistant and four of seven ABT-737-sensitive cases clustered with subgroup 1. In general, the two clusters were well separated, and, as expected, all of the 35 original CBF subgroup 1 cases were found to cluster together. qRT-PCR was done in untreated diagnostic samples of same primary samples as were treated with BV6). ***indicates a statistically highly significant difference in the expression levels (Po0.001), **stands for a statistically significant difference (Po0.005). Sensitive ¼ BV6 response with o50% viability at 10 mM BV6 treatment (labeled BV6 sens.); resistant X50% viability at 10 mM BV6 treatment (labeled BV6 res.).
Discussion
Based on GEP, we have previously been able to define two distinct CBF leukemia subgroups associated with outcome. 7 In order to investigate the functional relevance of the deregulated pathways found to differ between CBF subgroups, we defined here a cell line model resembling these two subgroups. As is the case for all model systems, this simplified model has limitations, but generally well represented the gene expression differences of the two CBF subgroups with regard to the pathways of interest, and importantly, results could be translated to primary CBF AML samples.
In this cell line model, our screen of different inhibitors showed that neither MAPKinase signaling intervention (IPA-3, PD98059) nor Stathmin pathway intervention (olomoucine, colchicine) revealed subgroup specific sensitivities. Thus, although members of these pathways were found to be differentially expressed among the CBF leukemia subgroups, this did not result in a corresponding deregulation on cellular/ functional level, which could be targeted by any of the used inhibitors. A possible explanation could be a complementary deregulation of the respective pathway in the other subgroup on a posttranscriptional level, possibly by microRNAs or other factors, thereby resulting in similar sensitivities to treatment.
In contrast, intervention in apoptotic signaling revealed subgroup-specific sensitivity of cell lines to treatment, demonstrating the relevance of the deregulation at mRNA level for the separation of the two CBF subgroups. For both BV6 and ABT-737, differences in treatment sensitivity correlated to expression levels of the target. As the Smac mimetic BV6 inhibits cIAP1 (cellular inhibitor of apoptosis protein 1), cIAP2 and XIAP (X-linked inhibitor of apoptosis), 16 overexpression of BIRC2 and BIRC3 (encoding cIAP1 and cIAP2, respectively) in CBF subgroup 2 cases matched the greater BV6 sensitivity of group 2 cell lines (Supplementary Figure S8) . In contrast, the two BV6 resistant cell lines, HEL (group 2) and OCI-AML2 (group 1), both expressed BIRC2 and BIRC3 at levels comparable to the other cell lines of their respective group. Although there were also no differences with regard to the expression levels of other qRT-PCR-measured genes involved in apoptosis, it has been reported that some cell lines might show no BV6 sensitivity due to a lack in TNF. 14, 30 However, both resistant cell lines in our study expressed TNF at a level comparable to the sensitive cell lines (data not shown). Thus, the definite cause remains open, but possibly these two cell lines harbor additional, yet unknown aberrations preventing their response to IAP inhibition. For treatment with the BCL2 inhibitor ABT-737, we observed a higher sensitivity in group 1 cell lines, in line with the fact that BCL2 itself was overexpressed in the CBF subgroup 1 cases compared with subgroup 2 cases. Two cell lines, MONO-MAC-1 (group 1) and MV4-11 (group 2), showed an ABT-737 sensitivity characteristic for the converse group, which could be explained by their respective BCL2 expression levels.
Given these findings, we assume that of the pathways differentially expressed among the CBF subgroups, deregulated apoptotic signaling accounts for a substantial part of the functional differences between the two subgroups. As simultaneous treatment with the IAP inhibitor BV6 and the AML standard treatment ara-C suggested additive to synergistic effects in cell lines, this combination treatment represents a promising approach to be further investigated for a potential clinical use.
Although cell lines are very useful model systems, they also entail drawbacks, such as their limited reflection of diverse patients with the same diagnosis and their acquired aberrations due to extensive culturing. Therefore, we extended our study to evaluate treatment effects also in primary CBF leukemia samples. Consistent with our findings in cell lines, diagnostic CBF AML samples exhibited differential sensitivity to treatment with ABT-737 and BV6. This raised the question whether target gene expression levels were correlated with sensitivity to inhibitor treatment.
In contrast to the cell line results, ABT-737 response was not associated with expression levels of BCL2 in the primary CBF AML samples. This was also reported in studies of acute lymphoblastic leukemia 31 and AML (cell lines and primary samples of relapsed/refractory patients), 32 although others did see a correlation of BCL2 expression levels to ABT-737 treatment sensitivity in small cell lung cancer xenografts. 33, 34 As reported by others for both de novo and acquired resistance to ABT-737, we could correlate sensitivity to ABT-737 treatment to MCL1 expression levels. 32, [34] [35] [36] Using GEP to find predictive signatures for treatment sensitivity might be a beneficial strategy, and first results have been reported for leukemia/lymphoma cell lines recently, 37 which need to be validated in primary samples and in the clinical context. Taking all findings together, there is still a need to decide on an adequate biomarker for a clinical treatment with ABT-737 or a related BCL2 inhibitor, and expanded studies like ours employing primary samples combined with GEP should help in this regard. In the past few years, several BCL2 inhibitors have entered clinical trials, showing so far only limited activity. 38, 39 Only very recently, the first results of a phase 1 study with navitoclax (ABT-263), the orally bioavailable analog of ABT-737, have shown promising clinical responses in lymphoid malignancies, usually expressing increased BCL2. 40 As it has also been reported that BCL2 protein levels in blasts are an important independent predictive factor for survival in newly diagnosed, intensively treated AML patients, 41, 42 this gives further incentive to use BCL2 inhibitors in the treatment of AML, in combination with standard cytotoxic treatment.
For BV6 treatment, in accordance with our cell line results, sensitivity in CBF AML samples correlated with significantly elevated BIRC2 and BIRC3 expression levels, as well as with significantly elevated XIAP and NFKB1 expression levels. As BV6 is an IAP inhibitor, this association was not surprising, and fit well into the described mode of action. 16 IAPs were originally described as caspase inhibitors, but meanwhile were found to also modulate nuclear factor (NF)-kB signaling and inflammation. 16 Interestingly, NF-kB is reported to induce BIRC2 (cIAP1), BIRC3 (cIAP2) and XIAP expression in a positive feedback loop, 43 while cIAP1 and cIAP2 are positive regulators of canonical NF-kB signaling and suppress the non-canonical pathway. Thus, cIAPs have both pro-and anti-apoptotic properties, as not only overexpression, but also loss of cIAPs can lead to NF-kB activation, survival of tumor cells and chemoresistance. 16, 44 Furthermore, Smac mimetic-and TNFinduced cell death depends on RIPK1, 14, 30, [45] [46] [47] a multifunctional protein that can promote either survival or cell death depending on its posttranslational modifications. For example, once ubiquitinated, RIPK1 can serve as an essential adapter molecule for the activation of NF-kB, while it promotes the formation of a RIPK1/FADD/caspase-8 proapoptotic complex when it is deubiquitinated. Interestingly, RIPK1 was expressed at significantly higher levels in BV6-sensitive cases compared with resistant cases. Due to the fact that IAP expression or function is deregulated in many cancers, including hematological malignancies, several IAP-targeting agents are currently being tested in (early) clinical trials. 14, 15, 48 Identification of molecular markers to select patients that should be sensitive to treatment will be crucial, and GEP represents a valuable approach in this respect.
We found that sensitivity to BV6 treatment correlated with gene expression profiles characteristic for the previously defined superior outcome CBF AML subgroup. 7 As classification according to the two CBF subgroups was not available a priori for the primary CBF AML samples treated with BV6 in this study, we profiled their gene expression and clustered them with the 93 previously described GEPs. This approach allowed us to assign a CBF subgroup label to these newly profiled primary samples based on their association with either the inferior or superior outcome group, consequently showing the association of BV6-resistant cases with the inferior CBF AML outcome group. In summary, all our data point towards apoptosis signaling, and more specifically IAPs, as the underlying deregulation to differentiate CBF leukemia subgroups independently of their respective karyotypes and secondary mutations (for example FLT3, KIT, NRAS). Therefore, therapies targeting IAPs, and also BCL2, should yield improved results for both CBF AML subgroups, and further studies to validate and more extensively test the preliminary effects observed in combination of ara-C and BV6 are indicated.
